vTv Therapeutics Inc. (VTVT) Stock Score, Valuation & Financial Research

vTv Therapeutics Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for VTVT

vTv Therapeutics Inc. does not currently have a complete Wall Street Score. The stored market price is USD 31.10. These figures are a research snapshot, not a buy or sell recommendation.

What vTv Therapeutics Inc. does

vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an oral, small-molecule, liver-specific glucokinase activator targeting Type 1 diabetes. Another key investigational drug is HPP737, an oral phosphodiesterase type 4 (PDE4) inhibitor that does not cross the blood-brain barrier (non-CNS penetrant), designed to treat inflammatory conditions and psoriasis. Beyond these, vTv Therapeutics' broader clinical portfolio includes: TTP273, an oral small-molecule GLP-1 receptor agonist addressing postprandial glucose excursions in cystic fibrosis-related diabetes. HPP3033, which employs a non-electrophilic strategy to activate the Nrf2 pathway for chronic conditions linked to oxidative stress. Azeliragon, a RAGE antagonist being evaluated for inflammatory lung disorders, notably severe COVID-19, alongside pancreatic and breast cancers. HPP971, an Nrf2 activator aimed at renal diseases, developed in collaboration with pharmaceutical partners. Furthermore, vTv holds a licensing agreement with Reneo Pharmaceuticals, Inc. for the development and commercialization of its peroxisome proliferation-activated receptor delta agonist program, which features the compound HPP593. The company has also established various other licensing and research collaborations with entities such as Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Newsoara Biopharma Co., Ltd., JDRF International, and Novo Nordisk A/S. Established in 2015, vTv Therapeutics is headquartered in High Point, North Carolina, and operates as a subsidiary of MacAndrews & Forbes Incorporated.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

vTv Therapeutics is a clinical-stage biopharmaceutical company that focuses on the research and development of oral small molecule drug candidates. The company currently does not generate revenue from product sales and relies on capital raises, such as private placements, to fund its ongoing research, development, and clinical trial operations.

Products and services

  • The company's lead product candidate is cadisegliatin (TTP399), a novel, liver-selective glucokinase activator currently in Phase 3 clinical trials for the treatment of type 1 diabetes.

Brands and product families

  • cadisegliatin (TTP399) — Lead product candidate currently in Phase 3 clinical trials for type 1 diabetes. Source

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on third-party contract research organizations to conduct and manage its clinical trials; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Cantex Pharmaceuticals, Inc. — A licensing agreement under which Cantex obtained exclusive worldwide rights to develop and commercialize azeliragon, a RAGE antagonist. Source

Business strengths to evaluate

  • Clinical-stage pipeline focused on novel small molecule drug candidates Source

Business risks and research considerations

  • History of operating losses and dependence on additional financing to fund operations Source
  • Risks associated with clinical trial enrollment, regulatory approval, and commercialization of product candidates Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

VTVT financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 31.10
Market capitalization:
81.4M (currency not supplied)
Revenue:
USD 36.84M
Net income:
USD -4.76M
Free cash flow:
USD -25.26M
Cash:
USD 86.64M
Total debt:
USD 0.00
EPS:
USD -0.11

What stands out

  • Free cash flow is USD -25.26M, negative for the stored period.
  • The balance sheet shows USD 86.64M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -68.6% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -12.9% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 86.64M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for VTVT

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can VTVT fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is VTVT likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for VTVT to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of VTVT's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-02.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research VTVT

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.